Chemoradiotherapy facilitates siglec-10+/siglec-9+ macrophage-mediated impairment of CD24+/MUC16+ tumor cell elimination and enhances PD-L2 dependent immunosuppression in cervical cancer

Wenzhi Kong & Jinwei Miao et al. · 2026-03-09

The post-treatment recurrence after chemoradiotherapy remains a major clinical challenge in cervical cancer, and the underlying mechanisms remain incompletely understood. In this study, single-cell RNA sequencing analysis of human cervical cancer tissues before and after concurrent chemoradiotherapy (CCRT) revealed that cervical cancer tumor cells exhibited enhanced stemness along with upregulated expression of CD24 and MUC16 following CCRT. Meanwhile, tumor-associated macrophages exhibited upregulated expression of Siglec-10 and Siglec-9 after CCRT. Siglec-10
Links
DOIPubMed
Journal
Cancer Immunology, Immunotherapy
TL;DR

In cervical cancer following CCRT, CD24+/MUC16+ tumor cells might interact with Siglec-10+/Siglec-9+ macrophages to suppress tumor cell elimination and upregulate PD-L2 expression, thereby promoting T cell dysfunction, tumor immune evasion, disease recurrence, and ultimately poorer patient prognosis.

AI-generated by Semantic Scholar

Authors
Wenzhi Kong, Penglin Liu, Jiamin Zhang, Qun Liu, Mengqi Deng, Chunyu Xu, Junqi He, Jinwei Miao
Funding
Capital Medical University Laboratory for Clinical Medicine and Gynecological Tumor Precise Diagnosis and Treatment Innovation Studio. Funding